Who
Praveen Tyle
Director
Company insider
Files Form 4 as: Director, Kiora Pharmaceuticals; Director, Skye Bioscience; EVP, R&D, Lexicon Pharmaceuticals; Senior Vice President, Bausch & Lomb.
In numbers
- Trades disclosed
- 87
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Feb 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 19 Aug 2024filed 19 Aug 2024 | KPRX Kiora PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $20K5,000 at $3.96 | filing |
| 1 Jul 2024filed 3 Jul 2024 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,778 at $0.00 | filing |
| 29 Feb 2024filed 4 Mar 2024 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 6 Nov 2023filed 6 Nov 2023 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,110 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 25 Aug 2023filed 29 Aug 2023 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,472,692 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 5 Jan 2023filed 9 Jan 2023 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 5 Jan 2023filed 6 Jan 2023 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 1 Feb 2022filed 3 Feb 2022 | KPRX Kiora Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 14 Sep 2021filed 16 Sep 2021 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Jul 2021filed 26 Jul 2021 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 28 Feb 2021filed 2 Mar 2021 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,990 | filing |
| 28 Feb 2021filed 2 Mar 2021 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —9,727 | filing |
| 28 Feb 2021filed 2 Mar 2021 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —26,600 | filing |
| 28 Feb 2021filed 2 Mar 2021 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —28,690 | filing |
| 28 Feb 2021filed 2 Mar 2021 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $119K16,560 at $7.19 | filing |
News
Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveyKPRX · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Praveen Tyle; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.